bioMerieux and Ipsen Sign Theragnostics Agreement to Develop Companion Test for New Breast Cancer Treatment.
Business Wire › September 17, 2007
Linked as:
Extract
bioMerieux and Ipsen Sign Theragnostics Agreement to Develop Companion Test for New Breast Cancer Treatment.
MARCY L'ETOILE, France & PARIS -- Regulatory News:
bioMerieux and Ipsen (Paris:IPN) announce today that they have signed an agreement by which bioMerieux will develop a companion test for a new breast cancer drug undergoing clinical evaluation by Ipsen. The development will be co-funded by bioMerieux and Ipsen. Ipsen is developing a novel breast cancer therapy, BN 83...See the full content of this document
Sponsored links
